Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Alan Hirzel, Jonathan Milner, Peter Keen, Louise Patten

Premium

Abcam, a Cambridge, UK-based provider of antibody microarrays, this week announced a series of management changes.

Alan Hirzel has been appointed CEO, succeeding Jonathan Milner. Hirzel previously was chief markeing officer at Abcam and has served on its board since January. Milner will continue to serve as deputy chairman of Abcam's board and remains the company's largest shareholder.

Abcam also said this week that Peter Keen will not seek re-election to the company's board. Keen has sat on Abcam's board since 2005, where he was chairman of the remuneration and audit committees, as well as senior independent director. Abcam said that Louise Patten will assume the senior independent director role following the company's annual general meeting in November.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.